Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696214 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
A Phase 4 study of Asthma, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01696214 is a Phase 4 study of Asthma that has completed, run by University of California, San Diego. The registered enrollment target is 20 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01696214, a Phase 4 study of Asthma, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the pilot (SAPS) protocol is to determine the feasibility and utility of implementing the provisional design of the full scale TOM trial (e.g., the six month treatment period, the impact of the smoking cessation intervention). There is no active hypothesis for the Vanguard Protocol.
Conditions Studied
Interventions
- DRUG Fluticasone 250 mg/salmeterol 50 mg
- DRUG Montelukast 10mg
- DRUG Theophylline 400 mg
- DRUG ipratropium
Study Locations (1)
California
- Airway Research & Clinical Trials Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696214
The ClinicalTrials.gov registry entry for NCT01696214 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Fluticasone 250 mg/salmeterol 50 mg is the first listed.
NCT01696214 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01696214 about?
NCT01696214 is a clinical study titled "A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial". The primary aim of the pilot (SAPS) protocol is to determine the feasibility and utility of implementing the provisional design of the full scale TOM trial (e.g., the six month treatment period, the impact of the smoking cessation intervention). There is no active hypothesis for the Vanguard Protoc...
What is the current status of trial NCT01696214?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-10. Estimated completion is 2016-11.
What conditions does trial NCT01696214 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01696214?
The interventions under investigation include: Fluticasone 250 mg/salmeterol 50 mg (DRUG), Montelukast 10mg (DRUG), Theophylline 400 mg (DRUG), ipratropium (DRUG).
Who is sponsoring clinical trial NCT01696214?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01696214 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.